District Of Columbia is currently home to 853 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Blood Purification for the Treatment of Pathogen Associated Shock
NCT05011656
Recruiting
This study is a multi-center, randomized controlled feasibility trial to evaluate the initial safety and efficacy of a novel extracorporeal blood purification (EBP) therapy in critically ill patients with pathogen associated shock across 15 U.S. sites. Adults (18 years old and older) admitted to the ICU with all of the following: • Pathogen associated shock defined as: * The need for vasopressors to maintain mean arterial pressure (MAP) ≥ 65 mmHg despite adequate fluid resuscitation * Presence... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: George Washington University, Washington, District of Columbia
Conditions: Septic Shock
Register for Updates
SELUTION 4 De Novo Small Vessel IDE Trial
NCT05946629
Recruiting
Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as reference vessel diameter (RVD) of 2.00 mm to 2.75 mm, in support of a pre-market approval (PMA) application to the United States (US) FDA. The Study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a par... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Coronary Artery Disease
Register for Updates
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
NCT05074810
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Georgetown University Medical Center, Washington, District of Columbia
Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation
Register for Updates
Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
NCT04889430
Recruiting
The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/31/2025
Locations: Georgetown University Lombardi Cancer Center, Washington, District of Columbia
Conditions: Atypical Hemolytic Uremic Syndrome
Register for Updates
Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)
NCT06806930
Recruiting
The goal of this clinical trial is to determine how the duration of hormone blocking (endocrine) therapy given prior to surgery (called "neoadjuvant" treatment) affects breast cancer. The main questions the trial aims is answer are: 1. How breast cancer responds to endocrine therapy given prior to surgery? 2. To predict tumor pre-operative endocrine prognostic index (PEPI) score for subjects enrolled in cohort B or C Participants with early-stage breast cancer (Stage I-III) who are eligible fo... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
01/29/2025
Locations: George Washington-Medical Faculty Associates, Washington, District of Columbia
Conditions: Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Carcinoma, Breast
Register for Updates
Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery
NCT03904862
Recruiting
This is a multi center, Phase I, Phase II and surgical study of the CX-4945 drug (silmitasertib sodium) for patients with recurrent SHH (Sonic Hedgehog) medulloblastoma
Gender:
ALL
Ages:
3 years and above
Trial Updated:
01/29/2025
Locations: Children's National Medical Center, Washington, District of Columbia
Conditions: Medulloblastoma, Childhood, Medulloblastoma Recurrent, Medulloblastoma
Register for Updates
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
NCT05710328
Recruiting
This phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG) positron emission tomography/computed tomography (PET/CT) works in predicting response to standard of care chemotherapy prior to surgery in patients with HER2-positive stage IIa-IIIc breast cancer. FDG is a radioactive tracer that is given in a vein before PET/CT imaging and helps to identify areas of active cancer. PET and CT are imaging techniques that make detailed, computerized pictures of areas inside... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
Register for Updates
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
NCT01838512
Recruiting
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Local Institution - 0057, Washington, District of Columbia
Conditions: Multiple Myeloma
Register for Updates
Exploring the Effect of the Transcendental Meditation® Technique on Migraine Frequency and Functionality: a Single Arm Study
NCT06695156
Recruiting
This research will explore the effect of the Transcendental Meditation® Technique on migraine intensity and frequency. It will be a single-arm pilot study involving 30 participants recruited from migraine treatment facilities and support groups in the US.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
01/27/2025
Locations: Georgetown Headache Center and DC area, Washington, District of Columbia
Conditions: Migraine, Migraine with or Without Aura
Register for Updates
Fecal Microbiota Transplant National Registry
NCT03325855
Recruiting
A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness
Gender:
ALL
Ages:
All
Trial Updated:
01/27/2025
Locations: MedStar Georgetown University Hospital, Georgetown, District of Columbia
Conditions: Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
Register for Updates
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
NCT05734066
Recruiting
This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors. This is followed by the phase 2 portion, to further assess the effectiveness and safety in pediatric and young adult participants with recurrent/refractory Ewing sarcoma.
Gender:
ALL
Ages:
Between 2 years and 30 years
Trial Updated:
01/21/2025
Locations: Childrens National Hospital Michigan, Washington, District of Columbia
Conditions: Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma
Register for Updates
Intravesical BCG vs GEMDOCE in NMIBC
NCT05538663
Recruiting
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard treatment with intravesical BCG. The purpose of this study is to test whether Gemcitabine + Docetaxel is a better or worse treatment than the usual BCG therapy approach. The primary objective of this study is to determine the event free survival (EFS) of BCG-naïve high gr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2025
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Non-muscle-invasive Bladder Cancer
Register for Updates